Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Laserscope (NASDAQ LSCP) -- Ignore unavailable to you. Want to Upgrade?

To: David K. who wrote (214)	3/10/1998 7:48:00 PM
From: E.J. Neitz Jr	Read Replies (1) \| Respond to of 314

ANALYSIS OF LASERSCOPE AND UPDATE ON STOCK PRICE ACTION There has been a persistent block seller in LSCP shares recently. This is the same kind of action that occured a few years ago--driving the stock down to an unbelievable value. The selling at that time was not company specific, but related to a group of individuals that held a very large position on margin. As the stock price dropped below $5, they began to sell stock and continued to do so until their financial problems were resolved. After the selling--the stock rebounded, and a very nice gain was had by many. This represented a unique buying opportunity. It is my opinion that something similiar is happening now. And again the selling is not company specific. Having followed this stock for many years, I believe the stock is extremely undervalued. Could be wrong, and could go lower--and I will buy more. The following is a summary of information on Laserscope. Pls note the return on equity, the revenue growth rate, very little debt, good current ratio and a stock price very near book value....as usual do your own research, and best wishes. March 1998 SUMMARY ANALYSIS OF LASERSCOPE Laserscope (LSCP) makes surgical, dermatological and theraputic laser systems, related assessories, disposibles and operating room equipment. Current Price $ 2..75 Book Value $2.54 Current Ratio 2.14 P/E 10 5 yr Growth % 86% NFY 1998 (Dec) Est EPS 0.50 Analyst Guidance 1 Buy/Hold (S&P Marketscope) Return on Equity 11.36% (MarketGuide) LT Debt to Equity 0.06 Total Debt to Equity 0.22 Recent News: 2-19-98 Fourth Qtr Results reflect shipment delays in operating room products, and inventory write-downs. CEO--writedown position company well for future, Sales in key European mkts remains strong,and co is opening new distribution channels in India and Hong Kong. Management is encouraged with acceptance of their PDT laser systems and the drug Photofrin to treat certain types of cancer. 1-12-98 FDA approves Laserscope PDT laser system for early-stage lung cancer 1-22-98 FDA approves company's new Erbium YAG laser for sale in the US.NWL Laser Technologie GmbH, a German manufacturer, manufactures the system and Laserscope holds a 32% stake in the company ( note: possible hidden value ) 2-28-98 Laserscope to Unveil three new Lasers at the American Academy of Dermatology Convention in Orlando, Fl on 2-28 through 3-3. Venus Erbium YAG System is smallest yet amoung most powerful on the market used for skin resurfacing. The Aura SL low powered configiuation of Aura Laser System is engineered for removal of spider veins, and age spots. The Levante Duel Mode Ruby Laser is indicated for the removal of hair, tattoos and pigmented lesions. End of 1997- Laserscope was selected by the Walt Disney Company to provide state of the art operating room equipment at the Medical Center of Celebration Village , a futuristic community recently opened near Orlando, Florida